The Healius Ltd (ASX: HLS) share price was in focus today after the company delivered a 2.2% increase in revenue to $1,373.2 million for FY26, with underlying net loss shrinking by 46.8% to $13.2 million.
What did Healius Limited report?
- Revenue from continuing operations rose 2.2% to $1,373.2 million (FY25: $1,344.2 million)
- Underlying EBITDA grew 8.1% to $258.6 million
- Underlying EBIT jumped 76.6% to $30.2 million
- Underlying loss after tax improved to $13.2 million from $24.8 million a year ago
- Reported loss after tax widened to $415.6 million, from $151.2 million, due chiefly to a $332 million non-cash goodwill impairment
- No dividend declared for FY26 (FY25: 41.3 cps special dividend)
What else do investors need to know?
Healius delivered operational improvements despite headwinds in the healthcare sector, including increased labour costs and limited Medicare indexation. Cost management helped contain annual spend, aided by a detailed workforce optimisation program reducing headcount by around 5%.
The Agilex Biolabs division performed strongly, growing revenue by 14.1% and EBITDA by over 67%. The company is reviewing strategic options for Agilex Biolabs, and an update for shareholders is expected ahead of the AGM.
Healius completed the major phase of its digital transformation program, with most collection centres now processing over 80% of episodes digitally. AIâdriven initiatives are delivering productivity gains and will continue to be rolled out across back-office and laboratory operations.
What’s next for Healius Ltd?
Looking ahead, Healius is focused on expanding higher margin revenue streams in diagnostics, capturing benefits from its completed digital platform rollouts, and further lifting network productivity. The group expects full-year labour cost pressures from regulatory changes, but remains confident about healthcare demand trends over the medium to long term.
The company maintains a strong balance sheet, ending FY26 with net debt of $32.8 million and well within its banking covenants. Management continues to target improved cashflow and margin restoration in FY27.
Healius Ltd share price snapshot
The Healius share price has been sold off over the past 12 months and is down 45%. This compares to a modest 2% gain by the S&P/ASX 200 index (ASX: XJO).
The post Healius posts FY26 revenue growth, narrows underlying loss appeared first on The Motley Fool Australia.
Should you invest $1,000 in Healius right now?
Before you buy Healius shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Healius wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.